Choose Your Country or Region

Iopamidol

Name: Iopamidol
Brand: Selleck Chemicals
SKU: S4532

Synonyms: Iopamiro, Isovue, Iopamiron, Niopam, Solutrast,B-15000,SQ-13396

Catalog No.S4532 Purity: 99.9%

Iopamidol (Iopamiro, Isovue, Iopamiron, Niopam, Solutrast,B-15000,SQ-13396) is a non-ionic, water-soluble radiographic contrast agent.

Iopamidol Chemical Structure

CAS: 60166-93-0

Purity & Quality Control

Batch: Purity: 99.9%

99.9

Other Others Products

Related compound libraries

Biological Activity

Description	Iopamidol (Iopamiro, Isovue, Iopamiron, Niopam, Solutrast,B-15000,SQ-13396) is a non-ionic, water-soluble radiographic contrast agent.

In vitro
In vitro	Iopamidol significantly decreases the rate of atrial contraction to a greater extent than either formulation of iodixanol. Iopamidol decreases papillary muscle force development more than the sodium formulation of iodixanol^[3].
Cell Research	Cell lines	Primary chondrocytes
	Concentrations	102 mg/mL, 204 mg/mL, or 408 mg/mL
	Incubation Time	16 h
	Method	Chondrocytes are plated on 96 well plates at a density of 1 x 10⁶ cells/cm² . After overnight incubation in standard tissue culture conditions, contrast agents (including iopamidol) are introduced to wells in varying concentrations. Following 16 hour incubation with PBS and contrast agents, chondrocyte viability is assessed using the Live/Dead stain kit and quantified using the CellTiter-Glo Luminescent Cell Viability Assay.

In Vivo
In vivo	Iopamidol increases systolic blood pressure (SBP), mean arterial pressure (MAP), and peak left ventricular pressure (LVP). Iopamidol increases LVP and LV end diastolic pressure to a greater extent than the cationic formulation of iodixanol. Thus iopamidol affects cardiovascular parameters more than iodixanol^[3].

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT01475097	Completed	Drug Safety	GE Healthcare\|i3 Statprobe	October 2011	Phase 4
NCT01376089	Completed	Patient Comfort and Safety	GE Healthcare\|i3 Statprobe	May 2011	Phase 4
NCT01252810	Completed	Chronic Renal Insufficiency\|Diabete Mellitus\|Congestive Heart Failure	GE Healthcare\|i3 Statprobe\|Medpace Inc.\|Biomedical Systems\|Rules-Based Medicine Inc.	November 2010	Phase 2
NCT01075217	Completed	Peripheral Arterial Occlusive Disease	Bracco Diagnostics Inc	April 2010	Phase 4
NCT00740207	Completed	Peripheral Arterial Occlusive Disease	Bracco Diagnostics Inc	September 2008	Phase 4

References

Chemical lnformation & Solubility

Molecular Weight	777.09	Formula	C₁₇H₂₂I₃N₃O₈
CAS No.	60166-93-0	SDF	Download Iopamidol SDF
Smiles	CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ( (128.68 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):